Global /China /Healthcare /Drug Manufacturers - General /600594

Guizhou Yibai Pharmaceutical Co., Ltd.

600594

• SSE: 600594 • Delayed

4.05CNY -1.7%

0.5985 USD

As of 16 June 2026, Guizhou Yibai Pharmaceutical Co., Ltd. has a market cap of $477.26M USD, ranking #15430 globally and #4829 in China. It ranks #1374 in the Healthcare sector, and #508 in the Drug Manufacturers - General industry.

Global Rank

15430

Country Rank

4829

Sector Rank

1374

Industry Rank

508

Key Stats

Market Cap

$477.26MUSD

3.23B CNY

Enterprise Value

$523.14MUSD

3.54B CNY

Revenue (TTM)

$254.05MUSD

1.72B CNY

EBITDA (TTM)

$8.07MUSD

54.62M CNY

Net Income (TTM)

-$51.64MUSD

-349.7M CNY

EBITDA Margin

3.2%

Profit Margin

-20%

PS Ratio

1.9

PB Ratio

1.4

EV/EBITDA

55.5

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Ya Qi Dou open_in_new

Employees

5,261

Founded

1995

Website

gzcci.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.7%	-11%	5.5%	0.5%	-3.8%	1.8%	15%	-33%	-32%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	600594 贵州益佰制药股份有限公司 Class A ISIN: CNE000001H03 Shares Out.: Shares Outstanding: 784.394M¹ Shares Float: 600.439M² TV: TradingView: SSE: 600594 SA: Stock Analysis: SHA: 600594 YF: Yahoo Finance: 600594.SS GF: Google Finance: SHA: 600594 BA: Barron's: 600594 MS: Morningstar: XSHG: 600594	4.05 CNY	TV: TradingView: SSE: 600594 SA: Stock Analysis: SHA: 600594 YF: Yahoo Finance: 600594.SS GF: Google Finance: SHA: 600594 BA: Barron's: 600594 MS: Morningstar: XSHG: 600594

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Guizhou Yibai Pharmaceutical Co., Ltd.

Guizhou Yibai Pharmaceutical Co., Ltd. researches, develops, produces, and sells pharmaceutical products in China. It offers products in the form of capsules, tablets, granules, syrups, small-volume injections, freeze-dried powder injections, lyophilized powder injections, pills, and oral solutions in the areas of tumor system, cerebrovascular, respiratory system, rheumatic bone, digestive system, pediatric, anti-infection, anti-inflammatory, analgesic, cancer, orthopedics, digestion, andrology, and urology. The company also engages in investment in the cultivation and breeding projects of medicinal materials; and agricultural products sale, as well as provides market information consulting services for medicinal materials. In addition, it is involved in the research and development, and information consulting services for health food. The company was founded in 1995 and is based in Guiyang, China.

Similar Companies

Industry: Drug Manufacturers - General (China)

Name	Market Cap (USD) diff.	PE	Country
Jiangsu Hengrui Pharmaceuticals Co.,Ltd SSE: 600276	$53.89B 364.89B CNY 11K%	44.9	China
WuXi AppTec Co., Ltd. SSE: 603259	$49.67B 336.36B CNY 10K%	17.2	China
Hansoh Pharmaceutical Group Company Ltd. SHEK: 3692	$28.52B 223.48B HKD 6K%	35.7	China
Innovent Biologics, Inc. SHEK: 1801	$18.8B 147.32B HKD 4K%	162.3	China
Sichuan Biokin Pharmaceutical Co.,Ltd. SSE: 688506	$16.52B 111.89B CNY 3K%	-	China
Akeso, Inc. SHEK: 9926	$16.01B 125.46B HKD 3K%	-	China

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 159K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 115K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 75K%	97.4	United States
Roche Holding AG SIX: RO	$322.73B 256.25B CHF 68K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.3B 215.59B GBP 61K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$275.68B 218.9B CHF 58K%	20.5	Switzerland

chevron_leftBack